Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;18(4):220205.
doi: 10.1183/20734735.0205-2022. Epub 2023 Jan 10.

Diagnosis and management of pulmonary hypertension related to chronic respiratory disease

Affiliations
Review

Diagnosis and management of pulmonary hypertension related to chronic respiratory disease

Anastasia Krompa et al. Breathe (Sheff). 2022 Dec.

Abstract

Pulmonary hypertension (PH) is a recognised and significant complication of chronic lung disease (CLD) and hypoxia (referred to as group 3 PH) that is associated with increased morbidity, decreased quality of life and worse survival. The prevalence and severity of group 3 PH varies within the current literature, with the majority of CLD-PH patients tending to have non-severe disease. The aetiology of this condition is multifactorial and complex, while the prevailing pathogenetic mechanisms include hypoxic vasoconstriction, parenchymal lung (and vascular bed) destruction, vascular remodelling and inflammation. Comorbidities such as left heart dysfunction and thromboembolic disease can further confound the clinical picture. Noninvasive assessment is initially undertaken in suspected cases (e.g. cardiac biomarkers, lung function, echocardiogram), while haemodynamic evaluation with right heart catheterisation remains the diagnostic gold standard. For patients with suspected severe PH, those with a pulmonary vascular phenotype or when there is uncertainty regarding further management, referral to specialist PH centres for further investigation and definitive management is mandated. No disease-specific therapy is currently available for group 3 PH and the focus of management remains optimisation of the underlying lung therapy, along with treating hypoventilation syndromes as indicated.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: A. Krompa has no conflicts of interests or disclosures. Conflicts of interest: P. Marino has received honoraria and travel bursaries from MSD, GlaxoSmithKline, Actelion and Janssen Pharmaceuticals, as well as education, research and service development grants from Actelion and Janssen Pharmaceuticals.

Figures

FIGURE 1
FIGURE 1
Processes involved in the pathophysiology of pulmonary hypertension in chronic lung disease and hypoxia. RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle.
FIGURE 2
FIGURE 2
Diagnostic algorithm for the investigation of pulmonary hypertension (PH) in patients with chronic lung disease (CLD). BNP: brain natriuretic peptide; TFT: thyroid-function tests; AI: autoimmune screen; CXR: chest radiography; HRCT: high-resolution computed tomography; CTPA: computed tomography pulmonary angiogram; Vʹ/Qʹ scan: ventilation/perfusion scan; MRI: magnetic resonance imaging; USS: ultrasound scan; RHC: right heart catheterisation; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; WU: Wood units.

Comment in

References

    1. Humbert M, Kovacs G, Hoeper MM, et al. . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618–3731. doi:10.1093/eurheartj/ehac237 - DOI - PubMed
    1. Hurdman J, Condliffe R, Elliot CA, et al. . Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41: 1292–1301. doi:10.1183/09031936.00079512 - DOI - PubMed
    1. Peacock AJ, Ling Y, Johnson MK, et al. . Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype? Pulm Circ 2020; 10: 2045894020914851. doi:10.1177/2045894020914851 - DOI - PMC - PubMed
    1. Klinger JR. Group III pulmonary hypertension: pulmonary hypertension associated with lung disease: epidemiology, pathophysiology, and treatments. Cardiol Clin 2016; 34: 413–433. doi:10.1016/j.ccl.2016.04.003 - DOI - PubMed
    1. Zhang L, Liu Y, Zhao S, et al. . The incidence and prevalence of pulmonary hypertension in the COPD population: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2022; 17: 1365–1379. doi:10.2147/COPD.S359873 - DOI - PMC - PubMed

LinkOut - more resources